Is TACHYCARDIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed TACHYCARDIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 16 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported TACHYCARDIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and TACHYCARDIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause TACHYCARDIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes TACHYCARDIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if TACHYCARDIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing TACHYCARDIA: 16
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where TACHYCARDIA is a reported side effect: 0.4806%

FDA reports of any drug causing TACHYCARDIA : 30429
Average percentage for all medicated patients where TACHYCARDIA is reported as a complication: 0.1907%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with TACHYCARDIA:

HEPARIN SODIUM INJECTION (2104 patients)
ASPIRIN (2006 patients)
CLOZARIL (1705 patients)
VIOXX (1633 patients)
FOSAMAX (1557 patients)
REMICADE (1415 patients)
SEROQUEL (1257 patients)
PREDNISONE (1092 patients)
ACETAMINOPHEN (1069 patients)
LASIX (936 patients)
LORAZEPAM (869 patients)
OMEPRAZOLE (841 patients)
DIGOXIN (815 patients)
LISINOPRIL (782 patients)
FUROSEMIDE (779 patients)
METHOTREXATE (744 patients)
LIPITOR (727 patients)
COUMADIN (702 patients)
ZOMETA (701 patients)
ALBUTEROL (695 patients)
CLOZAPINE (693 patients)
NEXIUM (693 patients)
FOLIC ACID (668 patients)
ATIVAN (663 patients)
IBUPROFEN (655 patients)
SYNTHROID (648 patients)
ATENOLOL (633 patients)
XANAX (620 patients)
SIMVASTATIN (614 patients)
DEXAMETHASONE (599 patients)
PROTONIX (599 patients)
ZOLOFT (598 patients)
LEVOTHYROXINE SODIUM (597 patients)
HYDROCHLOROTHIAZIDE (588 patients)
POTASSIUM CHLORIDE (583 patients)
ZOFRAN (564 patients)
PREDNISOLONE (559 patients)
NEURONTIN (526 patients)
PAXIL (519 patients)
LYRICA (519 patients)
RISPERDAL (515 patients)
AMBIEN (514 patients)
HEPARIN SODIUM (501 patients)
METOPROLOL TARTRATE (501 patients)
CYMBALTA (488 patients)
MORPHINE (484 patients)
DIAZEPAM (484 patients)
ZYPREXA (479 patients)
CYCLOPHOSPHAMIDE (474 patients)
CLONAZEPAM (471 patients)
PRILOSEC (468 patients)
ZOCOR (466 patients)
ALLOPURINOL (465 patients)
AREDIA (460 patients)
WARFARIN SODIUM (453 patients)
TOPROL-XL (451 patients)
VANCOMYCIN (446 patients)
FENTANYL (443 patients)
CARBOPLATIN (433 patients)
HUMIRA (431 patients)
PREDNISONE TAB (429 patients)
OLANZAPINE (425 patients)
SPIRIVA (424 patients)
LEVAQUIN (416 patients)
PLAVIX (413 patients)
BENADRYL (410 patients)
TRAMADOL HCL (406 patients)
NORVASC (401 patients)
VICODIN (400 patients)
METFORMIN HCL (395 patients)
CELEBREX (393 patients)
OXYCONTIN (390 patients)
PREVACID (372 patients)
MIRTAZAPINE (368 patients)
LEXAPRO (367 patients)
PROPOFOL (365 patients)
CITALOPRAM HYDROBROMIDE (364 patients)
DECADRON (363 patients)
INSULIN (354 patients)
CIPROFLOXACIN (351 patients)
DIOVAN (349 patients)
AVELOX (347 patients)
SINGULAIR (344 patients)
ADVAIR DISKUS 100/50 (339 patients)
RISPERIDONE (339 patients)
ALPRAZOLAM (338 patients)
STRATTERA (338 patients)
OXYCODONE HCL (335 patients)
FLUCONAZOLE (328 patients)
CISPLATIN (325 patients)
GABAPENTIN (323 patients)
FLUOROURACIL (320 patients)
RANITIDINE (315 patients)
EFFEXOR (313 patients)
AMITRIPTYLINE HCL (312 patients)
FORTEO (312 patients)
AMLODIPINE (310 patients)
LOVENOX (304 patients)
LOPRESSOR (304 patients)
COREG (304 patients)
ALLEGRA (295 patients)
MULTI-VITAMINS (292 patients)
PERCOCET (290 patients)
RAMIPRIL (287 patients)
VITAMIN D (286 patients)
HEPARIN (286 patients)
HYDROCORTISONE (284 patients)
SOLU-MEDROL (284 patients)
ABILIFY (278 patients)
METOPROLOL (277 patients)
ENALAPRIL MALEATE (277 patients)
TRAZODONE HCL (276 patients)
ACYCLOVIR (275 patients)
AMOXICILLIN (275 patients)
VELCADE (274 patients)
COLACE (272 patients)
YAZ (272 patients)
CALCIUM (266 patients)
CYTARABINE (266 patients)
VALPROATE SODIUM (263 patients)
CRESTOR (263 patients)
WELLBUTRIN (260 patients)
REGLAN (260 patients)
ACCUTANE (260 patients)
DURAGESIC-100 (258 patients)
DEPAKOTE (257 patients)
MORPHINE SULFATE (256 patients)
CONCERTA (256 patients)
LANTUS (255 patients)
TEMAZEPAM (255 patients)
METHYLPREDNISOLONE (254 patients)
COMPAZINE (254 patients)
BACTRIM (254 patients)
PANTOPRAZOLE (253 patients)
LANSOPRAZOLE (252 patients)
PARACETAMOL (251 patients)
PAROXETINE HCL (250 patients)
NITROGLYCERIN (250 patients)
TAXOL (248 patients)
ENBREL (245 patients)
SANDOSTATIN LAR (244 patients)
AUGMENTIN '125' (243 patients)
CELEXA (242 patients)
PROZAC (239 patients)
ZANTAC (236 patients)
MULTI-VITAMIN (236 patients)
LAMOTRIGINE (235 patients)
FLEXERIL (235 patients)
ETOPOSIDE (234 patients)
METOCLOPRAMIDE (234 patients)
TYLENOL (233 patients)
PREMARIN (230 patients)
TYLENOL (CAPLET) (230 patients)
FLUOXETINE (229 patients)
PACLITAXEL (228 patients)
AVASTIN (227 patients)
PROMETHAZINE (226 patients)
AVONEX (226 patients)
ONDANSETRON (226 patients)
METOPROLOL SUCCINATE (225 patients)
NAPROXEN (224 patients)
METRONIDAZOLE (224 patients)
PEPCID (221 patients)
DIPHENHYDRAMINE HCL (219 patients)
HALDOL (216 patients)
SPIRONOLACTONE (216 patients)
GLUCOPHAGE (214 patients)
CLONIDINE (213 patients)
HALOPERIDOL (212 patients)
LAMICTAL (210 patients)
COMBIVENT (209 patients)
CLARITHROMYCIN (208 patients)
AVANDIA (206 patients)
YASMIN (205 patients)
ASCORBIC ACID (205 patients)
SYMBICORT (204 patients)
VALIUM (204 patients)
ULTRAM (204 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (203 patients)
ALCOHOL (203 patients)
FLAGYL (203 patients)
AZITHROMYCIN (200 patients)
ZYRTEC (199 patients)
BACLOFEN (198 patients)
FERROUS SULFATE TAB (197 patients)
LORTAB (197 patients)
NUVARING (197 patients)
LIDOCAINE (196 patients)
ZITHROMAX (196 patients)
ALTACE (196 patients)
REVLIMID (195 patients)
DILAUDID (195 patients)
GAMMAGARD LIQUID (195 patients)
ALENDRONATE SODIUM (195 patients)
ATROVENT (194 patients)
KLONOPIN (193 patients)
ALDACTONE (193 patients)
CYCLOSPORINE (192 patients)
TAXOTERE (191 patients)
VENLAFAXINE HCL (191 patients)
CARBAMAZEPINE (190 patients)
FLOMAX (189 patients)
CARVEDILOL (188 patients)
CLARITIN (188 patients)
COZAAR (186 patients)
REMERON (186 patients)
CALCIUM CARBONATE (184 patients)
VITAMIN B-12 (184 patients)
NEUPOGEN (183 patients)
CARDIZEM (181 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about TACHYCARDIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.